injection site reaction

Also found in: Acronyms.

injection site reaction

An allergic, histaminic, or traumatic response of the skin and subcutaneous tissues to any substance introduced with a needle.

Patient care

The injection site should be carefully monitored for redness, swelling, necrosis, or purulence. The size of any injury should be measured and the patient's level of pain assessed. Management may depend on the nature of the introduced substance. In mild cases, topical application of a cold pack may alleviate symptoms. When a reaction occurs at the site of a vesicant injection (e.g., in patients receiving cancer chemotherapy), close monitoring by a physician or the injection of local antidotes may be required. Reactions that result in infection or necrosis may need to be treated with antibiotics or with surgical débridement.

References in periodicals archive ?
Injection site reactions were the most common adverse event, occurring in 78% of the mipomersen group and 31% of the placebo group.
The incidence of injection site reactions in the subcutaneous group was 2.
Although injection site reactions are relatively common, serious adverse effects have not been reported.
Besides, there were more injection site reactions with the use of anakinra and also the rate of serious infections with anakinra was touching statistical significance when compared to placebo.
The most common side effects of Cimzia are headache, upper respiratory infections, abdominal pain, injection site reactions and nausea.
Etanercept is administered by subcutaneous injections; the injection site reactions are typically limited to local hyperaemia and oedema and there is no evidence of local cell death or tissue necrosis (5).
The new version cut them almost in half and also slashed injection site reactions from 83.
In the ODYSSEY CHOICE I study in which all patients received an injection of Praluent or placebo every two weeks to maintain the blind, local injection site reactions were reported more frequently in patients treated with Praluent 300 mg every four weeks as compared to those receiving Praluent 75 mg every two weeks or placebo (16.
Most side effects were local injection site reactions, were mild to moderate and were resolved within a short period after drug application.
Headache and injection site reactions were the only adverse events more common with dupilumab than with placebo in the phase lib trial, with the incidence of injection site reactions showing a possible dose-response relationship.